HNGE vs ZOMDF: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
HNGE is the larger of the two ($8.61B market cap): the incumbent the market prices for continued execution (32.53x forward earnings). ZOMDF is the smaller challenger ($79.57M): more room to run, but more to prove. If the story you believe is HNGE's (Employer benefit penetration), HNGE is the more direct way to own it; if it is ZOMDF's (PulseVet consumables and the installed base), ZOMDF is.
HNGE vs ZOMDF: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | HNGE | ZOMDF | What it tells you |
|---|---|---|---|
| Market cap | $8.61B | $79.57M | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Price vs 52-week range | 79% of range | 13% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 28.72 | 0.77 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how HNGE and ZOMDF affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HNGE and ZOMDF share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HNGE and ZOMDF exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Hinge Health (HNGE) do?
Hinge Health is a digital musculoskeletal (MSK) care platform that provides physical therapy, pain management, and surgery prevention services through a combination of software, connected sensor hardware, and human care teams. The company's core offering combines a mobile and connected-sensor app with personalized exercise therapy programs, behavioral health support, and access to physical therapists, plus care navigation for surgery decisions. Customers are primarily large employers and health plans that purchase Hinge Health benefits for their members.
What does Zomedica (ZOMDF) do?
Zomedica Corp. is an Alberta-incorporated, Michigan-based animal-health company that sells therapeutic devices and point-of-care diagnostics to equine and companion-animal veterinarians. Its largest line is the PulseVet electrohydraulic shockwave system, acquired in 2021, which treats tendon, ligament, bone and wound conditions and earns recurring revenue from replacement applicators called trodes. It also sells Assisi pulsed electromagnetic devices, VETIGEL hemostatic gel, the TRUFORMA diagnostic platform, VETGuardian remote vital-signs monitoring and TRUVIEW digital cytology. A third segment, Development Services, began in the second half of 2025 and sells engineering, development and contract manufacturing work to outside partners. In September 2026 it announced a strategic partnership with Veterinary Study Groups (VMG) to bring its technologies to independent practices.
HNGE vs ZOMDF: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- HNGE drivers: Employer benefit penetration; Surgery prevention as ROI driver.
- ZOMDF drivers: PulseVet consumables and the installed base; TRUFORMA diagnostics and the Boehringer collaboration.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Digital health categories are competitive with various platforms targeting MSK and other condition areas, including the well-funded private Sword Health. For ZOMDF, the plainest risk is that Zomedica still loses money: ~$16 million of net loss over the trailing twelve months on Yahoo's figures, a period with no impairment charges, and it has never reported a profitable year.
HNGE or ZOMDF: which should you pick?
With growth, valuation and volatility this close (or not yet reported for one side), the drivers above are what separate HNGE from ZOMDF. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the HNGE and ZOMDF guides.
HNGE vs ZOMDF: the full fundamentals
HNGE. Hinge Health's valuation has moved from a story about reaching profitability to one about sustaining fast, profitable growth. At about 29x trailing and 33x forward earnings and 11x sales after a ~132% year-to-date gain, the shares sit below the ~$135 average target of 16 analysts, and the forward multiple is higher than the trailing one because consensus 2027 EPS of about $3.26 is below a trailing figure lifted by one-time items. Fourth-quarter consensus is ~$0.73 of EPS on ~$249 million of revenue.
ZOMDF. Trailing revenue is derived from ~$32.0 million in 2025 plus ~$28.2 million in the first nine months of 2026, less ~$21.6 million in the first nine months of 2025. At ~$0.08 a share, the market value of ~$80 million is about ~2.1 times sales and below book value (Yahoo shows ~0.77 times book). Subtracting ~$40.9 million of liquidity leaves an enterprise value near ~$39 million, about ~1.0 times sales. Because the company is unprofitable, earnings-based multiples do not apply.
Headline figures (approximate, November 2026): HNGE shows revenue (ttm) ~$801 million; Q3 2026 ~$235.0 million, up ~52% year over year, gross / operating margin ~86% / ~19%, net income (ttm) ~$166 million (Q3 2026 ~$57.4 million), adjusted eps (q3 2026) ~$0.71 vs ~$0.60 estimate; ZOMDF shows revenue (ttm) ~$38.7 million; Q3 2026 ~$9.9 million, up ~22%, net loss (ttm) ~$16 million; Q3 2026 ~$3.2 million (vs ~$6.1 million), gross margin (q3 2026) ~61%, market cap ~$80 million (~$0.08 a share, Nov 20, 2026).
The bottom line: HNGE vs ZOMDF
HNGE and ZOMDF are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined HNGE and ZOMDF exposure against your real portfolio. It is not an investment adviser.
Wondering how HNGE or ZOMDF fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Hinge Health
Ask Walnut's AI anything about HNGE and see how it fits what you own.
FAQ
What is the difference between HNGE and ZOMDF?
+
Hinge Health is a digital musculoskeletal (MSK) care platform that provides physical therapy, pain management, and surgery prevention services through a combination of software, connected sensor hardware, and human care teams. Zomedica Corp. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is HNGE or ZOMDF the better stock?
+
Neither is universally better. HNGE is the larger incumbent; ZOMDF is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, HNGE or ZOMDF?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both HNGE and ZOMDF?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of HNGE vs ZOMDF?
+
HNGE: Digital health categories are competitive with various platforms targeting MSK and other condition areas, including the well-funded private Sword Health. Employer benefits cycle and economic pressure can slow new logo growth. Member engagement determines outcomes and ROI to customers; engagement scaling must continue. Valuation is now the most visible risk: after a ~133% one-year gain the stock trades around 29x trailing earnings, 33x forward earnings, 11x sales and 29x book value as of November 2026, so a revenue deceleration or another small EPS miss like Q2 2026 (~$0.59 versus ~$0.62 expected) could move the shares sharply; the stock already fell about 16% from its 52-week high of ~$126, set after mid-October. Recent IPO dynamics persist, with continuing insider sales, including a ~$20.6 million sale disclosed in October 2026 and a ~$4.4 million sale disclosed in November, adding supply and shaping sentiment. ZOMDF: The plainest risk is that Zomedica still loses money: ~$16 million of net loss over the trailing twelve months on Yahoo's figures, a period with no impairment charges, and it has never reported a profitable year. Cash and securities fell to ~$40.9 million at September 30, 2026 from ~$44.1 million in June as the company funded losses, and a slower burn reduction would shorten its runway. The share count is very large at ~980 million, so even small per-share price moves change the market value meaningfully, and any future equity raise at today's prices would dilute heavily. OTCQB trading usually means thinner liquidity, wider spreads and less analyst coverage than an exchange listing; no analysts publish estimates on Yahoo. Shareholders rejected the executive pay proposal at the June 2026 meeting, a sign of investor frustration, and the stock is down about 26% over the year to November 20, 2026. Commercially, PulseVet faces other shockwave and rehabilitation devices, TRUFORMA competes with much larger diagnostic suppliers, and Development Services revenue depends on a few project contracts and already dipped quarter over quarter. Finally, the 2025 impairments show that past acquisitions have not earned back what was paid for them.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell HNGE or ZOMDF; figures are approximate and dated (as of November 2026). Verify current data before investing.